Bio Rad Company Leadership
BIO Stock | USD 338.48 0.00 0.00% |
Bio Rad's insiders are aggressively selling. The analysis of insiders' sentiment of trading Bio Rad Laboratories stock suggests that virtually all insiders are panicking at this time. Bio Rad employs about 7.7 K people. The company is managed by 28 executives with a total tenure of roughly 164 years, averaging almost 5.0 years of service per executive, having 275.0 employees per reported executive.
Norman Schwartz Chairman Chairman of the Board, President, Chief Executive Officer |
Timothy Ernst President Executive Vice President General Counsel and Secretary |
Bio Rad's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-09-06 | Andrew J Last | Disposed 3000 @ 329.94 | View | ||
2024-09-04 | James Barry | Disposed 623 @ 330.49 | View | ||
2024-06-13 | Michael Crowley | Disposed 369 @ 281.91 | View | ||
2024-02-27 | Michael Crowley | Disposed 3000 @ 336 | View | ||
2023-12-12 | Dara Wright | Disposed 1200 @ 299.16 | View | ||
2023-11-28 | Michael Crowley | Disposed 642 @ 305.1 | View |
Monitoring Bio Rad's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Bio |
Bio Rad's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Bio Rad's future performance. Based on our forecasts, it is anticipated that Bio will maintain a workforce of about 7700 employees by December 2024.Bio Rad Management Team Effectiveness
The company has Return on Asset of 0.0186 % which means that on every $100 spent on assets, it made $0.0186 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0979) %, meaning that it generated no profit with money invested by stockholders. Bio Rad's management efficiency ratios could be used to measure how well Bio Rad manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to grow to -0.05. In addition to that, Return On Capital Employed is likely to drop to 0.03. At this time, Bio Rad's Total Assets are very stable compared to the past year. As of the 28th of November 2024, Non Current Assets Total is likely to grow to about 9.7 B, while Other Current Assets are likely to drop about 92.3 M.As of the 28th of November 2024, Common Stock Shares Outstanding is likely to drop to about 29.1 M. In addition to that, Net Loss is likely to grow to about (4 B)
Bio Rad Workforce Comparison
Bio Rad Laboratories is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 98,503. Bio Rad holds roughly 7,700 in number of employees claiming about 8% of equities under Health Care industry.
Bio Rad Profit Margins
The company has Net Profit Margin of (0.3) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of 0.1 %, which entails that for every 100 dollars of revenue, it generated $0.1 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.63 | 0.5358 |
|
|
Bio Rad Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Rad insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Rad's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bio Rad insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Allison Schwartz over two months ago Disposition of tradable shares by Allison Schwartz of Bio Rad at 4.6 subject to Rule 16b-3 | ||
Ilan Daskal over two months ago Acquisition by Ilan Daskal of 456 shares of Bio Rad subject to Rule 16b-3 | ||
Michael Crowley over six months ago Acquisition by Michael Crowley of 520 shares of Bio Rad subject to Rule 16b-3 | ||
Michael Crowley over six months ago Disposition of 298 shares by Michael Crowley of Bio Rad at 4.6 subject to Rule 16b-3 | ||
Michael Crowley over six months ago Acquisition by Michael Crowley of 433 shares of Bio Rad subject to Rule 16b-3 |
Bio Rad Notable Stakeholders
A Bio Rad stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bio Rad often face trade-offs trying to please all of them. Bio Rad's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bio Rad's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Norman Schwartz | Chairman of the Board, President, Chief Executive Officer | Profile | |
Andrew Last | Chief Operating Officer, Executive Vice President | Profile | |
Jonathan DiVincenzo | President COO | Profile | |
Timothy Ernst | Executive Vice President General Counsel and Secretary | Profile | |
Ronald Hutton | Vice President Treasurer | Profile | |
Michael Crowley | Executive Vice President - Global Commercial Operations | Profile | |
Annette Tumolo | Executive Vice President and Presidentident, Life Science Group | Profile | |
Ilan Daskal | Chief Financial Officer, Executive Vice President | Profile | |
Giovanni Magni | Executive Vice President, Chief Strategy Officer | Profile | |
Roop CPA | Executive CFO | Profile | |
Roop Lakkaraju | Executive CFO | Profile | |
Jeffrey Edwards | Independent Director | Profile | |
Tania DeVilliers | Corporate Director | Profile | |
Arnold Pinkston | Independent Director | Profile | |
Alice Schwartz | Director | Profile | |
Gregory Hinckley | Lead Independent Director | Profile | |
Melinda Litherland | Independent Director | Profile | |
Courtney Enloe | General VP | Profile | |
Ajit Ramalingam | Senior Vice President Chief Accounting Officer | Profile | |
Lee Boyd | Senior Pacific | Profile | |
Yong Chung | Vice Relations | Profile | |
Jim Barry | Senior Manufacturing | Profile | |
Kurt DeLanghe | Middle Europe | Profile | |
Simon May | Executive Vice President and Presidentident - Life Science Group | Profile | |
Dara Wright | Executive Vice President and President of the Clinical Diagnostics Group | Profile | |
Matthew Werner | Senior Officer | Profile | |
Colleen Corey | Executive Resources | Profile | |
James Barry | Executive Group | Profile |
About Bio Rad Management Performance
The success or failure of an entity such as Bio Rad Laboratories often depends on how effective the management is. Bio Rad management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.06) | (0.05) | |
Return On Capital Employed | 0.03 | 0.03 | |
Return On Assets | (0.05) | (0.05) | |
Return On Equity | (0.07) | (0.07) |
Bio Rad Workforce Analysis
Traditionally, organizations such as Bio Rad use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bio Rad within its industry.Bio Rad Manpower Efficiency
Return on Bio Rad Manpower
Revenue Per Employee | 346.9K | |
Revenue Per Executive | 95.4M | |
Net Loss Per Employee | 82.8K | |
Net Loss Per Executive | 22.8M | |
Working Capital Per Employee | 328K | |
Working Capital Per Executive | 90.2M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (28.06) | Revenue Per Share 90.815 | Quarterly Revenue Growth 0.028 | Return On Assets 0.0186 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.